Persistence of lymphoblasts in bone marrow on day 15 and days 22 to 25 of remission induction predicts a dismal treatment outcome in children with acute lymphoblastic leukemia
Persistence of lymphoblasts in bone marrow on day 15 and days 22 to 25 of remission induction predicts a dismal treatment outcome in children with acute lymphoblastic leukemia
复制标题
DOI：
10.1182/blood.v100.1.43
复制
发表时间：
2002-07-01
期刊：
影响因子：
20.3
通讯作者：
Pui, CH
中科院分区：
文献类型：
--
作者：
Sandlund, JT;Harrison, PL;Pui, CH
我们确定了儿童急性淋巴细胞白血病（ALL）缓解诱导第15天和第22至25天形态可识别的持续性疾病对预后的重要性。在546名患者中，397名患者在第15天（+/- 1天）进行了可评估的骨髓（BM）检查，218名患者在第22至25天（+/- 1天）进行了可评估的骨髓（BM）检查。57例（14%）患者在第15天BM中存在持续性淋巴母细胞（大于或等于1%），27例（5.5%）患者在第22至25天存在持续性淋巴母细胞。与无淋巴细胞患者相比，在第15天（40%+/-6%）或在第22至25天（4%+/-3%）有淋巴细胞患者的5年无事件生存率（EFS）明显更差（分别为78%+/-2%和76%+/-2%）
We determined the prognostic importance of morphologically identifiable persistent disease at day 15 and days 22 to 25 of remission induction in childhood acute lymphoblastic leukemia (ALL). Among 546 patients entered on 2 consecutive protocols, 397 patients had evaluable bone marrow (BM) examinations on day 15 (+/- 1 day) and 218 on days 22 to 25 (+/- 1 day). Fifty-seven patients (14%) had persistent lymphoblasts (greater than or equal to1%) in the BM on day 15 and 27 patients (5.5%) had persistent lymphoblasts on days 22 to 25. The 5-year event-free survival (EFS) was significantly worse for patients with lymphoblasts on day 15 (40%+/-6%) or on days 22 to 25 (4%+/-3%) as compared to those without lymphoblasts on these dates (78%+/-2% and 76%+/-2%, respectively, P